Cite
HARVARD Citation
Vishwanathan, K. et al. (2020). A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacology research & perspectives. 8 (4), p. n/a. [Online].